Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms ARISE
  • Sponsors Amgen
  • Most Recent Events

    • 30 Sep 2021 Results of a pooled analysis assessing the risk of hypertension in patients with migraine who received Erenumab in clinical trials (NCT02066415 and NCT01952574) and two Phase 3 (NCT02456740 and NCT02483585) and in the postmarketing setting published in the Headache
    • 06 Jun 2021 Results of a pooled analysis from following clinical studies: from two phase 2 ; NCT02066415, NCT01952574 and two Phase 3 ; NCT02456740 and NCT02483585 assessing Erenumab 70 and 140 mg versus placebo for migraine prevention presented at the 63rd Annual Scientific Meeting of the American Headache Society
    • 06 Jun 2021 Results pooled data from two Phase 2 (NCT02066415 and NCT01952574) and two Phase 3 (NCT02456740 and NCT02483585) assess ischemic cardiovascular and cerebrovascular adverse events (ICCAE) presented at the 63rd Annual Scientific Meeting of the American Headache Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top